Loading…
Rapport Therapeutics, Inc. is projected to rise to $49.55 by 2027, a +25% move from its current price of $39.51. RAPP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $38.39 | $39.51 | $40.68 | +0.01% |
| May 30 | $37.93 | $39.52 | $41.17 | +0.02% |
| May 31 | $37.59 | $39.52 | $41.56 | +0.03% |
| Jun 1 | $37.30 | $39.53 | $41.89 | +0.04% |
| Jun 2 | $37.05 | $39.53 | $42.18 | +0.06% |
| Jun 3 | $36.83 | $39.54 | $42.45 | +0.07% |
| Jun 4 | $36.62 | $39.54 | $42.69 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $36.62 | $39.54 | $42.69 | +0.08% |
| Week 2 | $35.50 | $39.57 | $44.11 | +0.16% |
| Week 3 | $34.68 | $39.60 | $45.23 | +0.23% |
| Week 4 | $34.00 | $39.63 | $46.20 | +0.31% |
| Week 5 | $33.41 | $39.66 | $47.08 | +0.39% |
| Week 6 | $32.90 | $39.69 | $47.90 | +0.47% |
| Week 7 | $32.43 | $39.73 | $48.66 | +0.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate RAP-219 is an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders.
The company also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc.
in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Rapport Therapeutics trades under the symbol RAPP. The current price is $37.72 and the company sits in the Healthcare sector with a development focus on CNS disorders. Its market capitalization is $1.8B and its market rank is 2069.
The near-term outlook shows a neutral stance for 2026, with an average price of $37.72, a minimum of $25.55 and a maximum of $51.76. Beyond 2026, the forecast projects a bullish trajectory with rising average prices and upside potential through the late 2020s and into the 2030s and beyond.
A major floor 35.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.5% below — buyers have tended to step in here.
Price is pressing into resistance (1.1% away) — a breakout level to watch.
A major ceiling 12.4% above — clearing it would confirm fresh momentum.
Key RAPP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RAPP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.87 | Buy | $38.30 | Buy |
| MA 10 | $37.20 | Buy | $37.60 | Buy |
| MA 20 | $36.69 | Buy | $36.90 | Buy |
| MA 50 | $34.33 | Buy | $34.83 | Buy |
| MA 100 | $31.23 | Buy | $32.22 | Buy |
| MA 200 | $28.16 | Buy | $28.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.55 | Neutral |
| Stoch RSI (14) | 67.26 | Neutral |
| CCI (20) | 109.65 | Buy |
| Williams %R (14) | -7.55 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 3.86 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 92.45 | Sell |
| TRIX (15) | 0.35 | Buy |
| Awesome (5,34) | 1.34 | Buy |
| Ultimate (7,14,28) | 60.58 | Neutral |
| Momentum (10) | 2.27 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 39.34 | Buy |
| ADX (14) | 17.27 | Neutral |
| ATR (14) | 1.03 | Info |
The 30-day technical picture is bullish, with RSI14 at 60 and the 50-day simple moving average at $33.85 and the 200-day simple moving average at $27.91. Support is recorded at $33.00 and resistance at $39.93, framing a positive near-term bias.
The 30-day price range spans from $31.18 to $45.63, indicating a broad trading band over the period. Annualized volatility is reported at 60%, underscoring notable price movement potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.55 | $39.51 | $54.60 | 0% | Neutral | |
| $39.06 | $49.55 | $66.72 | +25% | Bullish | |
| $44.04 | $57.51 | $80.40 | +46% | Bullish | |
| $45.98 | $61.52 | $88.60 | +56% | Bullish | |
| $59.19 | $80.93 | $119.51 | +105% | Bullish | |
| $74.68 | $104.15 | $157.21 | +164% | Bullish | |
| $80.06 | $113.73 | $175.09 | +188% | Bullish | |
| $88.73 | $128.25 | $201.00 | +225% | Bullish | |
| $94.42 | $138.76 | $221.07 | +251% | Bullish | |
| $98.69 | $147.35 | $238.36 | +273% | Bullish | |
| $161.89 | $259.84 | $448.10 | +558% | Bullish | |
| $297.88 | $542.19 | $1,026.24 | +12.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $25.55 | $39.51 | $46.25 | +0.00% |
| June 2026 | $33.11 | $38.94 | $46.92 | -1.45% |
| July 2026 | $33.64 | $39.91 | $48.78 | +2.50% |
| August 2026 | $33.43 | $39.94 | $49.36 | +0.08% |
| September 2026 | $32.71 | $39.32 | $49.01 | -1.57% |
| October 2026 | $33.60 | $40.60 | $51.02 | +3.26% |
| November 2026 | $35.06 | $42.56 | $53.86 | +4.82% |
| December 2026 | $35.14 | $42.85 | $54.60 | +0.69% |
Click any year to see its month-by-month RAPP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RAPP could reach as high as $54.60, with a base case around $39.51 and support toward $25.55 — roughly 0% from $39.51. Price action looks broadly range-bound.
Expect RAPP to range from $39.06 to $66.72 through 2027. The $49.55 average target implies a +25% move from current prices. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The RAPP price prediction for 2028 points to an average of $57.51 (low $44.04, high $80.40) — a potential gain of +46% on today's $39.51. Momentum favours further upside here.
In 2029, RAPP is projected to trade between $45.98 and $88.60, averaging $61.52 — a potential gain of +56% from today's $39.51. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Rapport Therapeutics, Inc.'s 2030 outlook centres on $80.93, within a $59.19 to $119.51 range. That is up +32% on the projected 2029 average. That marks a +105% change versus current levels. Momentum favours further upside here.
By 2031, RAPP could reach as high as $157.21, with a base case around $104.15 and support toward $74.68 — roughly +164% from $39.51. Buyers look set to stay in control over this stretch.
Expect RAPP to range from $80.06 to $175.09 through 2032. The $113.73 average target implies a +188% move from current prices. That is up +9% on the projected 2031 average. Momentum favours further upside here.
The RAPP price prediction for 2033 points to an average of $128.25 (low $88.73, high $201.00) — a potential gain of +225% on today's $39.51. Buyers look set to stay in control over this stretch.
In 2034, RAPP is projected to trade between $94.42 and $221.07, averaging $138.76 — a potential gain of +251% from today's $39.51. That is up +8% on the projected 2033 average. Momentum favours further upside here.
Rapport Therapeutics, Inc.'s 2035 outlook centres on $147.35, within a $98.69 to $238.36 range. That is up +6% on the projected 2034 average. That marks a +273% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RAPP could reach as high as $448.10, with a base case around $259.84 and support toward $161.89 — roughly +558% from $39.51. Momentum favours further upside here.
Expect RAPP to range from $297.88 to $1,026.24 through 2050. The $542.19 average target implies a +12.7x move from current prices. That is up +109% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RAPP today (≈ 25.310048 RAPP) could be worth
$13,722.76
+$12,722.76 (+1272%) by 2050 · US Dollar
Based on the average projected RAPP price of $542.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RAPPwould be worth at today's price.
$1,000 invested in RAPP on May 27, 2025 (≈ 99.601594 RAPP) would be worth
$3,935.26
+$2,935.26 (+293.5%) today · 3.94× · US Dollar
Based on a RAPP entry price of $10.04 vs. today's $39.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.72 | $1,106.1 | +10.6% |
| 1 month ago | $35.4 | $1,116.1 | +11.6% |
| 3 months ago | $29.5 | $1,339.32 | +33.9% |
| 6 months ago | $29.71 | $1,329.86 | +33.0% |
| 1 year ago | $10.04 | $3,935.26 | +293.5% |
| All time (2.0y) ago | $20.8 | $1,899.52 | +90.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RAPP forecast.
Our base-case forecast reaches $79.00 around 2030.
Implied market cap at $79.00: $3.78B
The multi-year forecast shows a continued bullish tilt with meaningful upside from 2027 onward. In 2026 the avg is $37.72 with min $25.55, max $51.76 and ROI of 0% (sentiment NEUTRAL).
By 2030 the average price is projected at $73.73 with a min of $53.95 and a max of $108.84, delivering an estimated ROI of 95.5% and a bullish sentiment.
The forecast also envisions strong longer-term gains: in 2040 the average price is $224.38 (min $139.95, max $386.57) with ROI of 494.9% and a bullish sentiment, and by 2050 the average price reaches $456.89 (min $251.48, max $863.75) with ROI of 1111.3% and a bullish sentiment.
These figures indicate substantial upside across the horizon, though they are estimates and actual results may differ. The outlook remains bullish for the longer term, reflecting projected growth in the asset’s value through mid-century while recognizing the inherent uncertainty in any forecast.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $73.73, with a min of $53.95 and a max of $108.84, for a projected ROI of 95.5% and a bullish sentiment.
The longer-term forecast is bullish from 2027 onward, with the average price rising to $93.93 by 2031 and to $456.89 by 2050, and ROI reaching 1111.3% by 2050. The 2026 view is neutral, indicating mixed near-term signals but substantial potential over the longer horizon.
Yes. The 2030 maximum in the forecast is $108.84, which exceeds $100, supported by a 2030 average of $73.73 and a bullish sentiment.
The current price is $37.72 and the market capitalization is $1.8B. The market rank is 2069.
For 2040, the average price is $224.38 with a min of $139.95 and a max of $386.57, representing a projected ROI of 494.9% and a bullish sentiment.
Rapport Therapeutics, Inc. Community Discussion
0Share your Rapport Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.